What is The Cigna's latest dividend and current dividend yield?

What guidance did The Cigna's management provide for the next earnings period?

What is the revenue and EPS growth rate for The Cigna year over year?

What is The Cigna's gross profit margin?

What factors drove the changes in The Cigna's revenue and profit?

Did The Cigna beat or miss consensus estimates last quarter?

What does The Cigna do and what are its main business segments?

What were the key takeaways from The Cigna's earnings call?

- **Revenue & EPS Growth**: 2025 adjusted EPS $29.84 (+9%), 2026 target ≥$30.25.
- **PBM Model Shift**: 50%+ clients on rebate-free by 2028, $7B cost relief over 10 years.
- **Specialty Momentum**: 14% YoY growth, biosimilar savings ($0 out-of-pocket for HUMIRA).
- **Margin Stability**: 2026 MCR 83.7-84.7%, stable PBM margins despite regulatory changes.
- **Tax Consideration**: Potential 1% tax rate increase from GPO relocation.

**【CEO Summary Section】**
- Full year 2025 adjusted revenue: $275 billion (+11% YoY), adjusted EPS: $29.84 (+9% YoY). 
- FTC settlement delivers $7B in cost relief over 10 years, with new rebate-free PBM model reducing out-of-pocket costs for 100M customers.
- 2026 outlook: Adjusted EPS ≥$30.25, driven by specialty growth and disciplined pricing.

**【CFO Financial Commentary】**
- Evernorth: Specialty & Care revenue +14% YoY ($26.7B), Pharmacy Benefits Services revenue $36.3B. 
- Cigna Healthcare: 2025 MCR 84.2%, 2026 MCR guidance 83.7-84.7%, with 2026 EPS ≥$30.25.
- 2026 capital deployment: $1.3B capex, $1.6B dividends, 2026 cash flow $9B.

**【Q&A Key Highlights】**
- **PBM Model Transition**: 50%+ Evernorth clients on rebate-free model by 2028, margin profile stable vs legacy model.
- **Tax Impact**: Moving GPO to US could increase effective tax rate by up to 1% over time.
- **Specialty Growth**: 14% YoY revenue growth, biosimilar adoption (e.g., HUMIRA) driving $0 patient cost.
- **MLR Trends**: 2026 MCR reflects elevated cost trends, but disciplined pricing (+60+ bps rate hikes) supports margin.
- **Membership**: 2026 medical customers ~18.1M (flat YoY), Select segment growth offsetting exchange decline.

The Cigna Group (CI) Q4 2025 Earnings Call Transcript

**Key Takeaways:**
- **EPS Outlook**: 2025 adjusted EPS reaffirmed at $29.60+, with 2026 growth despite PBS margin compression. 
- **PBS Transformation**: 50% of business in rebate-free model by 2028, simplifying economics and lowering consumer costs. 
- **Specialty Growth**: 10%+ revenue growth in Specialty & Care, driven by biosimilar adoption and new partnerships. 
- **Stop-loss Recovery**: 2026 MCR target of 83-84%, with full recovery by 2027. 
- **Strategic Renewals**: 3 large clients renewed through 2030, ensuring long-term PBS stability. 
- **Regulatory Leadership**: Leading industry on continuity of care, prior auth simplification, and IVF affordability.

**【CEO Summary Section】**
- **Third-quarter results**: Revenue of $6.7 billion and adjusted earnings of $7.83 per share, driven by strategic investments in innovation and partnerships (e.g., Shields Health Solutions). 
- **New rebate-free pharmacy model**: Launched to improve affordability, with 50% of business transitioning by end-2028, emphasizing transparency and lowest prices at the counter. 
- **Market dynamics**: Generic drugs 1/3 cheaper in the U.S. than globally, but brand-name drugs cost 4x as much, highlighting affordability challenges. 

**【CFO Financial Commentary】**
- **Full-year 2025 outlook**: Reaffirmed adjusted EPS of at least $29.60, with Specialty & Care Services growing 10% and Pharmacy Benefit Services (PBS) facing margin compression due to large client renewals. 
- **Segment performance**: 
  - **Evernorth**: $60.4 billion in revenues, $1.9 billion in pretax adjusted earnings, with Specialty & Care up 10% and PBS stable. 
  - **Cigna Healthcare**: $10.9 billion in revenues, $1 billion in pretax adjusted earnings, with medical care ratio (MCR) at 84.8% due to individual exchange updates. 
- **Cash flow**: $3.4 billion in Q3, with 2025 cash flow expected to remain strong. 

**【Q&A Highlights】**
- **Pharmacy Benefit Services (PBS) margin impact**: 2026 EPS growth expected despite PBS margin compression, with 50% of PBS business in rebate-free model by 2028. 
- **Client renewals**: 3 large clients (e.g., DoD, Prime Therapeutics) renewed through 2030, reducing short-term EPS by ~$0.50 but ensuring long-term durability. 
- **Specialty growth**: Biosimilar adoption (e.g., HUMIRA) driving 11% adjusted earnings growth in Specialty & Care, with $7 million prescriptions in Q3. 
- **Cigna Healthcare strategy**: Stop-loss business repriced for 2026, with MCR expected to improve to 83-84% by 2027. 
- **Regulatory response**: Proactive collaboration with administration on continuity of care, prior authorization simplification, and IVF affordability.

The Cigna Group (CI) Q3 2025 Earnings Call Transcript

- **Q2 Financial Strength**: $67.2B revenue, $7.20 adjusted EPS, reaffirming $29.60+ 2025 guidance amid elevated costs.
- **Evernorth Growth**: Specialty & Care Services +12% (normalized), PBS retention >95%, biosimilar adoption (e.g., STELARA $0 cost).
- **Strategic Innovations**: AI virtual assistant, GLP-1 $200/month cap program, Arkansas PBM injunction win.
- **2026 Outlook**: PBS mid-90s retention, stop-loss margin recovery, exchange business pricing focus.
- **Market Leadership**: Service-based model, public-private partnerships, biosimilar TAM ($100B+ by 2030).

**【Management Opening Remarks】**
- Ralph Giacobbe introduced the executives and outlined the call structure, emphasizing forward-looking statements and financial measures.
- The company reaffirmed its full-year 2025 adjusted EPS guidance of at least $29.60 despite elevated medical cost trends.

**【CEO Summary Section】**
- **Financial Highlights**: Q2 revenue of $67.2 billion and adjusted EPS of $7.20, maintaining the long-term 10-14% CAGR target.
- **Strategic Differentiators**: Service-based model, leadership continuity, and innovation (e.g., AI virtual assistant for customer experience).
- **Market Positioning**: Focus on affordability, transparency, and public-private partnerships (e.g., prior authorization simplification with HHS).

**【CFO Financial Commentary】**
- **Segment Performance**: Evernorth (60% of earnings) saw Pharmacy Benefit Services (PBS) pretax adjusted earnings of $833M and Specialty & Care Services growth of 12% (normalized for VillageMD impact).
- **Cigna Healthcare**: Pretax adjusted earnings of $1.1B with a medical care ratio of 83.2%, managing elevated costs through disciplined pricing.
- **Outlook**: Full-year 2025 guidance reaffirmed, with Q3 EPS expected to be ~25% of the annual target.

**【Q&A Key Highlights】**
- **2026 Selling Season**: Mid-90s retention in PBS, focus on affordability and personalization, and biosimilar adoption (e.g., STELARA $0 patient cost program).
- **Regulatory Response**: Arkansas PBM legislation injunction viewed as positive, emphasizing choice and innovation in affordability solutions.
- **Exchange Business**: Reduced scale (400K vs. 1M in 2023) with 2026 price increases prioritizing margin over growth.
- **Stop-Loss Recovery**: 13% premium growth in Q2, with margin improvement expected over 2025-2026 renewals.
- **GLP-1 Market**: New $200/month patient cost cap program driving employer adoption, with economic contribution in line with expectations.


The Cigna Group (CI) Q2 2025 Earnings Call Transcript

- **Q1 2025 Strong Performance**: $65.5B revenue, $6.74 EPS, raising full-year guidance to $29.60.
- **Evernorth Growth Drivers**: 19% Specialty revenue growth, 14% PBS expansion, GLP-1 innovations (9M enrolled).
- **Cigna Healthcare Momentum**: 9% Select segment growth, stop loss recovery on track.
- **Strategic Focus**: Operational efficiency, biosimilar adoption, GLP-1 affordability solutions.
- **Risks**: Arkansas legislation limiting choice, economic uncertainty.

**【CEO Summary Section】**
- Cigna delivered Q1 2025 revenue of $65.5 billion and adjusted EPS of $6.74, raising full-year EPS guidance to at least $29.60.
- CEO emphasized long-term growth strategy through Evernorth (health services) and Cigna Healthcare (integrated benefits), with 10%-14% EPS growth target.
- Highlighted customer-focused initiatives: improving access, affordability, and transparency in healthcare.
- Announced strategic optimization program to enhance operational efficiency.

**【COO Business Drivers】**
- **Evernorth Performance**: 
  - Specialty & Care Services revenue up 19% to $23.9B, driven by biosimilar adoption (e.g., interchangeable Humira and Stelara).
  - Pharmacy Benefit Services (PBS) revenue +14%, processing 2B prescriptions with 90% generics.
  - GLP-1 innovation: 9M enrolled in EncircleRx, launching EnReachRx and EnGuide for enhanced patient support.
- **Cigna Healthcare Growth**: 
  - 9% revenue growth, Select segment customers +9% YoY (3M total).
  - Stop loss MCR tracking to expectations, with 2025 margin recovery plan on track.
  - MCR 82.2%, favorable trends in surgical and OB services offsetting specialty cost pressures.

**【CFO Financial Outlook】**
- **Evernorth 2025 Guidance**: Pre-tax earnings ≥$7.2B, driven by PBS and Specialty growth.
- **Cigna Healthcare 2025 Guidance**: Pre-tax earnings ≥$4.125B, MCR 83.2%-84.2%.
- **Capital Management**: $2.6B share buybacks YTD, 43.1% debt-to-capital ratio, disciplined cash deployment.

**【Q&A Key Themes】**
- **GLP-1 Market Dynamics**: Biosimilar competition reducing costs, 9M enrolled in EncircleRx, 50% employers cover weight management.
- **Arkansas Legislation**: Opposed as restrictive, limiting choice and increasing costs; small market impact for Cigna.
- **Stop Loss Recovery**: 2025 MCR tracking to plan, 100% margin recovery by 2026.
- **Medicare Divestiture**: $20M Q1 earnings impact from delayed sale, ongoing focus on core businesses.
- **Economic Resilience**: No material impact on enrollment or cost trends, prudent planning assumptions maintained.

Cigna (CI)-2 May 25-2025 Q1 Earnings call transcript

- **2024 Results**: $247B revenue (+27%), $27.33 EPS (+9%), but Q4 miss due to stop-loss costs. Biosimilar adoption hits 50% for HUMIRA.
- **2025 Outlook**: EPS target $29.50, Evernorth growth 9%, Cigna Healthcare margin recovery over 2-3 years.
- **Investments**: $150M in patient transparency, share buybacks dominate capital deployment.
- **Stop-Loss Recovery**: 100bps margin recapture by 2027, 2025 MCR elevated but improving post-2026.


**【CEO Summary Section】**
- Full year 2024 revenue grew 27% to $247 billion, with adjusted EPS of $27.33 (9% YoY increase). Dividends and share repurchases totaled $8.6 billion.
- Fourth quarter results were below expectations due to higher-than-expected medical costs in stop-loss products within Cigna Healthcare. Management expects to recapture 100 basis points of margin over 2-3 years.
- Evernorth Health Services delivered strong performance, with Specialty & Care Services revenue up 18% and biosimilar adoption reaching nearly 50% for HUMIRA scripts by year-end.
- Accelerated investments in patient transparency and affordability initiatives, including $150 million in incremental costs for 2025.

**【CFO Financial Commentary】**
- 2024 full year adjusted EPS of $27.33 fell short of expectations due to stop-loss margin pressure. Fourth quarter Cigna Healthcare MCR was 87.9%, above target range.
- 2025 outlook: Adjusted EPS of at least $29.50, with Evernorth expected to contribute $7.2 billion in earnings (9% YoY growth). Cigna Healthcare adjusted earnings of $4.1 billion (mid-single-digit growth).
- Capital deployment: $10 billion in cash flow, $1.6 billion in dividends, and majority of Medicare sale proceeds ($12 billion) allocated to share repurchases.

**【Q&A Key Takeaways】**
- **Stop-Loss Dynamics**: 2024 pressure driven by high-cost claimants (specialty meds, high acuity surgeries). 2025 MCR expected to remain elevated but improving in 2026+. 60% of Cigna Healthcare premium unaffected by stop-loss trends.
- **Evernorth Growth**: Specialty & Care Services growth fueled by biosimilars and new drug launches. 2025 guidance reflects maturation of large contracts and incremental investments.
- **Capital Strategy**: Share buybacks remain priority, with disciplined M&A focus on bolt-on opportunities. Dividend increased 8% to $1.51 per share.


Actual																	4.69	5.81	4.41	3.51	4.73	5.24	5.73	4.77	6.01	6.22	6.04	4.96	5.41	6.13	6.77	6.79	6.47	6.72	7.51	6.64	6.74	7.2	7.83	8.08
Forecast																	4.3587	5.15	4.2432	3.6777	4.3717	4.9604	5.2241	4.7236	5.1824	5.4872	5.7159	4.8645	5.2597	6.0304	6.68	6.5375	6.22	6.4313	7.2276	7.8271	6.3511	7.1559	7.6398	7.8803
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+7.60%	+12.82%	+3.93%	-4.56%	+8.20%	+5.64%	+9.68%	+0.98%	+15.97%	+13.35%	+5.67%	+1.96%	+2.86%	+1.65%	+1.35%	+3.86%	+4.02%	+4.49%	+3.91%	-15.17%	+6.12%	+0.62%	+2.49%	+2.53%

CI

CI fundamentals

CI Q4 2025 Earnings

Earnings Call

You can ask Aime

CI

CI fundamentals

CI Q4 2025 Earnings

Earnings Call

CI Earnings Call Summary for Q4/20258:30 AM on Feb 5, 2026

CI Earnings Call Summary for Q3/20258:30 AM on Oct 30, 2025

CI Earnings Call Summary for Q2/20258:30 AM on Jul 31, 2025

CI Earnings Call Summary for Q1/20258:30 AM on May 2, 2025

CI Earnings Call Summary for Q4/20248:30 AM on Jan 30, 2025

You can ask Aime